Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s): ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

TSX:ATE - Post by User

Antibe Therapeutics Inc(Pre-Merger) > EMAIL FROM DANLEGAULT ABOUT INSIDE SELLING

<< Previous

Bullboard Posts

Next >>

Comment by mstrmndon Jun 07, 2020 9:56pm

381 Views

Post# 31122683

RE:EMAIL FROM DANLEGAULT ABOUT INSIDE SELLING

I can independently confirm as well

Should not be material in the grand scheme of things unless it can be proven otherwise beyond doubt

This article is damaging however...shame or gain based on perspective - last chance either way

Bigger question is, why is there a stampede to the left when the party at the Maldives is to the right? Is something on the table?

In a Tsunami the water recedes first ;) ETA to Tsunami? Any takers? Somethings coming...

GLTA